Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Fisher

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Oncotarget|December 10, 2017
The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-<i>O</i>-phosphateJoanna Shepherd, Matthew Fisher, Abigail Welford, et al.
Biomedical Optics Express|October 31, 2017
Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomographyRobert A Byers, Matthew Fisher, Nicola J Brown, et al.
Journal of Clinical Anesthesia|June 20, 2017
Scheduling non-operating room anesthesia cases in endoscopy: Using the sandbox analogyMitchell H Tsai, Leah A Cipri, Stephen E O'Donnell, et al.
BMJ Open|October 6, 2018
Qualitative protocol for understanding the contribution of Australian policy in the urban planning, justice, energy and environment sectors to promoting health and health equityFran Baum, Toni Delany-Crowe, Matthew Fisher, et al.
Plos One|May 9, 2012
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary taleSheila Harris, Madeleine Craze, Jillian Newton, et al.
Chemmedchem|October 4, 2018
Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer TherapyAndrew W Brown, Toby Holmes, Matthew Fisher, et al.
Journal of Biomechanical Engineering|March 12, 2026
An Exploratory Assessment of Associations Between Serum Estrogen to Progesterone Ratio and Anterior Cruciate Ligament Size, Biomechanics, and T2* Relaxation Time in the Porcine ModelJacob Thompson, Danielle Howe, Emily Griffith, et al.
Health Promotion Journal of Australia : Official Journal of Australian Association of Health Promotion Professionals|September 12, 2021
Barriers to digital health services among people living in areas of socioeconomic disadvantage: Research from hospital diabetes and antenatal clinicsToby Freeman, Matthew Fisher, Kristen Foley, et al.
Medical Engineering & Physics|October 12, 2010
Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agentsSimon Akerman, Constantino Carlos Reyes-Aldasoro, Matthew Fisher, et al.
Plos One|June 21, 2018
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivoDarren L Lath, Clive H Buckle, Holly R Evans, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Oncotarget|December 10, 2017
The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-<i>O</i>-phosphateJoanna Shepherd, Matthew Fisher, Abigail Welford, et al.
Biomedical Optics Express|October 31, 2017
Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomographyRobert A Byers, Matthew Fisher, Nicola J Brown, et al.
Journal of Clinical Anesthesia|June 20, 2017
Scheduling non-operating room anesthesia cases in endoscopy: Using the sandbox analogyMitchell H Tsai, Leah A Cipri, Stephen E O'Donnell, et al.
BMJ Open|October 6, 2018
Qualitative protocol for understanding the contribution of Australian policy in the urban planning, justice, energy and environment sectors to promoting health and health equityFran Baum, Toni Delany-Crowe, Matthew Fisher, et al.
Plos One|May 9, 2012
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary taleSheila Harris, Madeleine Craze, Jillian Newton, et al.
Chemmedchem|October 4, 2018
Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer TherapyAndrew W Brown, Toby Holmes, Matthew Fisher, et al.
Journal of Biomechanical Engineering|March 12, 2026
An Exploratory Assessment of Associations Between Serum Estrogen to Progesterone Ratio and Anterior Cruciate Ligament Size, Biomechanics, and T2* Relaxation Time in the Porcine ModelJacob Thompson, Danielle Howe, Emily Griffith, et al.
Health Promotion Journal of Australia : Official Journal of Australian Association of Health Promotion Professionals|September 12, 2021
Barriers to digital health services among people living in areas of socioeconomic disadvantage: Research from hospital diabetes and antenatal clinicsToby Freeman, Matthew Fisher, Kristen Foley, et al.
Medical Engineering & Physics|October 12, 2010
Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agentsSimon Akerman, Constantino Carlos Reyes-Aldasoro, Matthew Fisher, et al.
Plos One|June 21, 2018
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivoDarren L Lath, Clive H Buckle, Holly R Evans, et al.
Pageof 7